Vasoactive pharmacotherapy is now being widely used as practical and reliable method for the treatment of the patients with erectile dysfunction. But the individual vasoactive agent has limitations in its clinical success and potential for side
effects
So, the synergistic effect and low drug volume of each vasoactive drug in polypharmacotherapy of erectile dysfunction have made it possible to reduce both systemic and local complications with excellent success rate. A total of 223 patients with
erectile dysfunction underwent a trial of intracavernous self injection therapy with Trimix (the mixture of papaverine, phentolamine and prostaglandin E1). Major underlying diseases were DM(115patients, 51.6%), hypertension (11 patients, 4.9%),
spinal
injury (three patients, 1.3%) and prior pelvic surgery (three patients, 1.3%). The volume of drug used ranged between 0.04 and 0.6ml(average:0.19ml). After a mean followup of 7.6 months (3-15 months), 141 patients (63.2%) left in the home
injection
program and among them, 125 patients (88.6%) had very high satisfaction. The drop-out rat was 36.8%(82 of 223) with most of the cases during early home phase. The causes of drop-out rate was 36.8% (82 of 223) with most of the cases during early
home
phase. The causes of droup-out were the fear of neddle or injection, inadequate response to injection, loss of interest and complications. Priapism (six patients, 3.8%), pain (six patients, 3.8%) and granuloma on injection site (one patient, 06%)
were
noticible complications, but coporal fibrosis and systemic side effect were not noticed.
In conclusion, Trimix intracavernosal injection therapy is minimally invasive, simple, relatively sfae and, most of all, very effective method for the treatment of the patients with erectile dysfunctions.
|